JAGX - Jaguar Health, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300

Full Time Employees60

Key Executives

NameTitlePayExercisedYear Born
Ms. Lisa A. ConteFounder, CEO, Pres & Director771.4kN/A1959
Dr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer & Chair of Scientific Advisory Board539.04kN/A1963
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. Counsel520.29kN/A1963
Mr. Ian H. Wendt M.B.A.Chief Commercial Officer441.31kN/A1968
Dr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.477.66kN/A1958
Ms. Carol R. Lizak M.B.A.Chief Financial OfficerN/AN/A1964
Mr. Peter HodgeSr. Director of Investor Relations, Bus. Devel. & Special EventsN/AN/AN/A
Dr. Karen J. Brunke Ph.D.Exec. VP of Corp. & Bus. Devel.N/AN/A1953
Mr. David SesinChief Manufacturing OfficerN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California.

Corporate Governance

Jaguar Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.